LRMR · Larimar Therapeutics, Inc.
$3.93
+0.10 (+2.61%)
At close · Jul 21
Market Cap
$408.26M
Shares
103.88M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$0
FY2019
Net Income
-$165.67M
-105.5%
FY2025
Diluted EPS
-$1.32
-57.1%
FY2024
Operating Cash Flow
-$113.2M
-60%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $0 | — | — | — | — | — | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | |
| $152.7M | $154.22M | $73.28M | $27.67M | $24.25M | $38.4M | $31.41M | $20.79M | $47.93M | $40.84M | $39.94M | $54.62M | $27.39M | $9.56M | $11.54M | |
| $19.72M | $18.27M | $17.61M | $14.09M | $12.28M | $12.07M | $11.4M | $2.42M | $13.19M | $12.16M | $18.29M | $19.2M | $8.14M | $4.22M | $2.25M | |
| — | — | — | — | — | — | — | $5.55M | — | — | $1.4M | — | — | — | — | |
| $172.43M | $172.5M | $90.89M | $41.76M | $36.53M | $50.47M | $42.8M | $23.21M | $61.12M | $53M | $58.23M | $73.81M | $35.53M | $13.78M | $13.79M | |
| -$172.43M | -$172.5M | -$90.89M | -$41.76M | -$36.53M | -$50.47M | -$42.8M | -$23.21M | -$61.12M | -$53M | -$58.23M | -$73.81M | -$35.53M | -$13.78M | -$13.79M | |
| $1.57M | — | — | — | — | — | — | $1.77M | $1.9M | $165K | $529K | $806K | $870K | — | $97K | |
| $1.61M | — | — | — | — | — | — | $1.99M | $1.89M | $996K | — | — | — | — | — | |
| $6.42M | $6.82M | $10.29M | $4.81M | $1.17M | -$171K | $322K | $82K | -$246K | $971K | $347K | -$473K | -$946K | -$247K | -$89K | |
| — | -$165.67M | -$80.6M | -$36.95M | -$35.36M | -$50.64M | -$42.48M | -$23.18M | -$61.37M | -$52.03M | -$57.88M | -$74.29M | -$36.48M | -$14.03M | -$13.88M | |
| — | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | |
| -$166.01M | -$165.67M | -$80.6M | -$36.95M | -$35.36M | -$50.64M | -$42.48M | -$23.13M | -$61.37M | -$52.03M | -$57.88M | -$74.29M | -$36.48M | -$14.03M | -$13.88M | |
| -$61.37M | — | — | — | — | — | — | — | — | — | -$57.88M | -$74.29M | -$36.57M | -$14.24M | -$13.95M | |
| -$166.05M | -$165.77M | -$80.54M | -$36.84M | -$35.39M | -$50.64M | -$42.48M | -$23.13M | -$61.34M | -$52.01M | -$57.75M | -$74.46M | -$36.51M | -$14.03M | — | |
| USD/shares | — | — | -$1.32 | -$0.84 | -$1.37 | -$2.95 | -$3.57 | — | — | — | — | — | — | — | — |
| USD/shares | — | — | -$1.32 | -$0.84 | -$1.37 | -$2.95 | -$3.57 | — | — | — | — | — | — | — | — |
| shares | — | — | 61.26M | 43.9M | 25.76M | 17.16M | 11.88M | 6.09M | 32.23M | 27.43M | 27.3M | 26.76M | 12.19M | 729K | 709.68K |
| shares | — | — | 61.26M | 43.9M | 25.76M | 17.16M | 11.88M | 6.09M | 32.23M | 27.43M | 27.3M | 26.76M | 12.19M | 729K | 709.68K |
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Biotechnology median 8.68×
EV/EBIT
—
Biotechnology median 26.45×
P/E (TTM)
—
Biotechnology median 7.21×